Our findings described here demonstrate the first mutation in the
Cryba2 gene in any organism so far. The
Cryba2 gene is very closely linked to the γ-crystallin gene cluster and belongs to the same superfamily of β/γ-crystallins. Mutations in the corresponding genes have been shown in many cases to cause congenital dominant cataracts in mouse and man (for a recent review see Ref.
24). Surprisingly, no cataract mutation could be attributed to the
Cryba2 gene up to now. Here we show that a point mutation in the
Cryba2 gene leads to smaller lens in juvenile mice and later to cortical cataracts in heterozygotes and to a total cataract in homozygous mutants.
The Aca30 mutation characterized by its small lenses was linked to mouse chromosome 1, but the region of the Cryg gene cluster at 65 to 66 Mb was excluded. In the critical 7.5 Mb-interval between 70.4 and 77.9 Mb the Cryba2 gene was by far the most likely candidate gene. The p.S47P mutation in Cryba2 is not present in other mouse strains, but co-segregates with the pathologic phenotype in the Aca30 line. Therefore, the p.S47P mutation is most likely causative for the small-lens phenotype of the Aca30 mutant line. Based on the regular histology of the mutant lenses and the expression pattern of Cryba2 in the lenses of the very young animals (mainly in the epithelial cells and the early secondary fiber cells), it might be speculated whether βA2-crystallin contributes to the thickness (volume) of the secondary lens fiber cells or to the speed of the terminal differentiation process in the transition zone from epithelial cells to the secondary fiber cells.
The lenses of the
Aca30 mutants are clear at the time when the lens size was measured (at 11 weeks); however, a cortical cataract is visible at 15 weeks progressing in homozygous mutants to total cataracts at 25 weeks of age. We expect progression to a similar clinical feature also in the heterozygous mutants at higher age. This brings the
Cryba2 gene in close relation to other
Cryb genes leading also to progressive cataracts in mice. The most prominent progressive cataract mutation is the Philly mouse forming the first sign of cataract in heterozygotes at 15 days after birth and having mature cataract at the age of 45 days
25 ; similar features have been observed in the other two
Crybb2 alleles,
Aey2 26 and
O377.
27 In contrast to these dominant findings in point-mutations of the
Crybb2 gene, the phenotype of the null mutant leads to recessive cataracts in the mouse being formed in the posterior and anterior cortex several months after birth; the severity of these cataracts increased with age.
9 Another progressive cataract (
Po) was characterized by a mutation in the
Cryba1 gene and leads to a cortical opacity when the mice open their eyes (i.e., 12 days after birth). The cataract progresses to a perinuclear zonular opacification and finally to a total cataract at the age of eight weeks. In homozygous mutants, the total cataract is already developed at eye opening.
28 No mutants of the remaining 3
Cryb genes (
Cryba4,
Crybb1 and
Crybb3) are reported; there exist only ES cell lines with targeted mutations (
http://www.informatics.jax.org; Aug 12, 2010).
In humans, the situation is a bit different: the only
CRYB gene with no mutation reported so far is the
CRYBA2 gene. Mutations in all other
CRYB genes are associated with dominant (or in a few cases also recessive), but congenital cataracts of different types (for a recent review see Ref.
24 and references therein). Therefore, it will be interesting to see whether a human mutation in
CRYBA2 is associated with a rather age-related cataract (like in the
Aca30 mouse) or with congenital cataract (like mutations in the other human
CRYB genes). Moreover, it might be important to test the hypothesis, if a slightly smaller lens might be understood as an early biomarker for age-related cataracts.
Since the overall lifespan of a mouse is approximately two years, a six-month-old mouse (∼25% of the total lifespan) might correspond to a 20-year-old human. However, this calculation does not account for the differences in the timing of developmental and aging processes among these two species. For example, mice are born with closed eyes and open their eye lids approximately two weeks after birth. In humans, this happens at the end of the first trimester of pregnancy. Moreover, the reproductive lifespan of (female) mice ranges from eight weeks to 20–35 weeks,
29 suggesting the age of a six-month-old mouse might correspond to a 50-year-old (female) human.
Finally, data from the Allen Brain Atlas (
http://mouse.brain-map.org) demonstrate that
Cryba2 is also expressed in various brain regions of the mouse; the midbrain shows the highest signal density. We have identified
Cryba2 transcripts in cDNA preparations of the entire brain and in particular of the cerebellum (data not shown). This is in line with findings in other
Cryb genes, particularly, with the βB2-crystallin–encoding gene.
27,30,31 However, according to the Allen Brain Atlas, the highest expression of mouse
Cryb genes shows the
Crybb1 gene, particularly in the cerebellum, the cerebral cortex, and in the olfactory bulb. In contrast, almost no expression in the brain was found for the
Cryba1 and
Cryba4 genes as well as for most of the γ-crystallin–encoding genes (except for
Crygb, which is expressed also in some brain region with its highest expression level in the dorsal region of the striatum). Even if the function of β-crystallins in the brain remains mainly speculative, ophthalmologists might be aware of additional neurologic deficits in cataract patients suffering from mutations in β-crystallin encoding genes, and additional research in this field should be initiated.
In conclusion, we report here the first mutation in the Cryba2 gene leading to a smaller lens in juvenile mice and to cataracts later in life. Therefore, the Aca30 mouse mutant might be used as a model for age-related cataracts in humans. Because of the expression of Cryba2 in the brain, neurologic effects of the mutation cannot be excluded.
Supported by National Genome Network Grants (NGFN, NGFN plus; Grants BMBF 01KW9923 and BMBF 01GS0850) and by EUMODIC (European Mouse Disease Clinic; Grant LSHG-2006-037188).
The authors thank Erika Bürkle, Jan Enke, Tommy Fuchs, Maria Kugler, and Monika Stadler for expert technical assistance.